Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid
- PMID: 3732891
- PMCID: PMC1433583
- DOI: 10.1136/gut.27.7.814
Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid
Abstract
Endotoxins in plasma were monitored during treatment in 18 patients hospitalised for acute exacerbation of Crohn's disease: systemic endotoxaemia was found on admission in all but one. The patients were randomly divided into two groups: one receiving treatment with total parenteral nutrition and steroids. To decrease the absorbable endotoxin pool, the other group was additionally treated with whole gut irrigation and 5-aminosalicylic acid was added to the lavage fluid. In most of these patients endotoxaemia cleared after intestinal lavage and they needed shorter hospitalisation. Earlier improvement was also indicated by a faster decrease of the Crohn's disease activity index and vanHees index. In the group receiving conservative treatment alone, endotoxaemia was controlled within three weeks. We conclude that endotoxaemia occurs in most patients suffering from active Crohn's disease. Control of endotoxaemia after intestinal lavage suggests that systemic endotoxaemia is caused by absorption of endotoxins from the gut. Earlier improvement after whole gut irrigation indicates its beneficial effect in active Crohn's disease.
Similar articles
-
Whole-gut irrigation as antiendotoxinaemic therapy in inflammatory bowel disease.Hepatogastroenterology. 1984 Apr;31(2):91-3. Hepatogastroenterology. 1984. PMID: 6724501
-
Endotoxaemia in patients with Crohn's disease: a longitudinal study of elastase/alpha 1-proteinase inhibitor and Limulus-amoebocyte-lysate reactivity.J Clin Chem Clin Biochem. 1988 Mar;26(3):117-22. doi: 10.1515/cclm.1988.26.3.117. J Clin Chem Clin Biochem. 1988. PMID: 3260268
-
Treatment of Crohn's disease with peroral 5-aminosalicylic acid.Gastroenterology. 1983 Dec;85(6):1350-3. Gastroenterology. 1983. PMID: 6354827 Clinical Trial.
-
The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.Ann Pharmacother. 1997 Jul-Aug;31(7-8):907-13. doi: 10.1177/106002809703100719. Ann Pharmacother. 1997. PMID: 9220055 Review.
-
Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.Pharmacotherapy. 1994 Jul-Aug;14(4):385-98. Pharmacotherapy. 1994. PMID: 7937276 Review.
Cited by
-
Differential regulation of TLR4 expression in human B cells and monocytes.Mol Immunol. 2010 Nov-Dec;48(1-3):82-8. doi: 10.1016/j.molimm.2010.09.008. Epub 2010 Oct 16. Mol Immunol. 2010. PMID: 20956019 Free PMC article.
-
Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis.Inflamm Bowel Dis. 2010 May;16(5):856-69. doi: 10.1002/ibd.21132. Inflamm Bowel Dis. 2010. PMID: 19924809 Free PMC article.
-
Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals.AIDS. 2009 Nov 27;23(18):2387-95. doi: 10.1097/QAD.0b013e328330b489. AIDS. 2009. PMID: 19855253 Free PMC article.
-
Trends in Diverting Loop Ileostomy vs Total Abdominal Colectomy as Surgical Management for Clostridium difficile Colitis.JAMA Surg. 2019 Oct 1;154(10):899-906. doi: 10.1001/jamasurg.2019.2141. JAMA Surg. 2019. PMID: 31268492 Free PMC article.
-
Inhibition of intestinal ascorbic acid uptake by lipopolysaccharide is mediated via transcriptional mechanisms.Biochim Biophys Acta Biomembr. 2018 Feb;1860(2):556-565. doi: 10.1016/j.bbamem.2017.10.010. Epub 2017 Oct 10. Biochim Biophys Acta Biomembr. 2018. PMID: 29030247 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical